BioNTech (BNTX) stock forecast for 2022
Last update: October 2, 2022 (08:28)Sector: Healthcare
The share price of BioNTech SE (BNTX) now
What analysts predict:: $233.03
52-week high/low: $369.68 / $117.08
50/200 Day Moving Average: $150.02 / $164.23
This figure corresponds to the average price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.
For BioNTech stocks, the 200-day moving average is the resistance level today.
Are you interested in BioNTech stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the BioNTech stock price in 2022. How much will one BioNTech share be worth in 2022?
Is it worth taking profit / loss on BioNTech stock now or waiting? What are analysts' forecasts for BioNTech stock?
We forecast BioNTech stock performance using neural networks based on historical data on BioNTech stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The BioNTech stock prediction results are shown below and presented as a graph, table and text information.
BioNTech stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for BioNTech analysts is $233.03.
Today 200 Day Moving Average is the resistance level (164.23 $).
50 Day Moving Average is the resistance level (150.02 $).
Historical and forecast chart of BioNTech stock
The chart below shows the historical price of BioNTech stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the BioNTech stock price can be found in the table below.
BioNTech (BNTX) Forecast for 2022
BioNTech information and performance
BioNTech SE is a German biotechnology company that develops and manufactures active immunotherapeutic agents for an individual approach to the treatment of serious diseases. The company is investigating messenger RNA (mRNA) -based drugs for use as individualized immunotherapy for cancer, as vaccines against infectious diseases and as protein replacement therapy for rare diseases, as well as developed cell therapy, new antibodies and small molecules, immunomodulators, as options cancer treatment. The company has developed an intravenous mRNA-based human therapeutic drug to bring individualized mRNA-based cancer immunotherapy to clinical trials and establish its own manufacturing process.
AN DER GOLDGRUBE 12, MAINZ, DE
Market Capitalization: 32 733 352 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 15 380 600 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: 3.082
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: 0.0449
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: -0.401
Quarterly Revenue Growth YOY: -0.398
Trailing PE: 3.082
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 8.87
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 1.113
Enterprise Value (EV) /Revenue
EV To EBITDA: 1.401
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 242685000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
BioNTech price target for 2021 by month
Target values for the price of one BioNTech share for Nov 2022.
Pessimistic target level: 124.59
Optimistic target level: 144.17
Target values for the price of one BioNTech share for Dec 2022.
Pessimistic target level: 130.39
Optimistic target level: 146.47
BioNTech (BNTX) stock dividend
BioNTech last paid dividends on 06/02/2022. The next scheduled payment will be on 06/17/2022. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Last Split Factor:
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.